Non-Tuberculous Mycobacterial (NTM) – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033

 Non-tuberculosis mycobacterial (NTM) lung infections, while less common than those caused by Mycobacterium tuberculosis, are transmitted via inhaled aerosolized droplets containing the infectious agents. Risk factors for NTM transmission include close living quarters, coughing, and failure to wear masks. Advanced age, immunosuppression, and corticosteroid use raise the risk of acquiring NTM microorganisms. Once inside the body, NTM microorganisms primarily settle in the lower airways, leading to an inflammatory response characterized by an influx of lymphocytes. This immune reaction releases cytokines and other mediators, resulting in pneumonia-like symptoms, including fever, weight loss, night sweats, decreased appetite, and energy loss. The prognosis of NTM lung infections is uncertain, particularly for immunocompromised patients. The prognosis may also vary based on the specific NTM infection type. Research suggests that Mycobacterium avium complex (MAC) infections have a more favorable prognosis, while Mycobacterial abscessus lung infections have higher mortality rates. Chronic underlying lung diseases, particularly Mycobacterial abscessus infection and the specific NTM infection type are significant predictors of mortality. NTM lung disease typically presents in three major clinical forms: fibro-cavitary, nodular bronchiectasis, and hypersensitivity pneumonitis, with clinical manifestations often resembling other lung infections and chronic diseases.

·       In the USA, the incidence of NTM is estimated at 4.73 cases per 100,000 annually.

 

Thelansis’s “Non-Tuberculous Mycobacterial (NTM) Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Non-Tuberculous Mycobacterial (NTM) treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).

 

KOLs insights of Non-Tuberculous Mycobacterial (NTM) across 8 MM market from the centre of Excellence/ Public/ Private hospitals participated in the study. Insights around current treatment landscape, epidemiology, clinical characteristics, future treatment paradigm, and Unmet needs.

Non-Tuberculous Mycobacterial (NTM) Market Forecast Patient Based Forecast Model (MS. Excel Based Automated Dashboard), which Data Inputs with sourcing, Market Event, and Product Event, Country specific Forecast Model, Market uptake and patient share uptake, Attribute Analysis, Analog Analysis, Disease burden, and pricing scenario, Summary, and Insights.

Thelansis Competitive Intelligence (CI) practice has been established based on a deep understanding of the pharma/biotech business environment to provide an optimized support system to all levels of the decision-making process. It enables business leaders in forward-thinking and proactive decision-making. Thelansis supports scientific and commercial teams in seamless CI support by creating an AI/ ML-based technology-driven platform that manages the data flow from primary and secondary sources.

Read more: Non-Tuberculous Mycobacterial (NTM) – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033

Tags: Non-Tuberculous Mycobacterial (NTM), Non-Tuberculous Mycobacterial (NTM) market outlook, Non-Tuberculous Mycobacterial (NTM) competitive landscape, Non-Tuberculous Mycobacterial (NTM) market forecast, Thelansis, Primary market research, KOL insights, Competitive Intelligence (CI)